|
GB1142508A
(en)
*
|
1966-04-27 |
1969-02-12 |
Whitefin Holding Sa |
Pyrrole derivatives
|
|
GB1154743A
(en)
*
|
1966-05-17 |
1969-06-11 |
Whitefin Holding Sa |
Aminoethanols
|
|
AU2337499A
(en)
|
1998-01-23 |
1999-08-09 |
National Jewish Medical And Research Center |
Method for treating inflammatory diseases using heat shock proteins
|
|
US7842470B2
(en)
|
2001-10-09 |
2010-11-30 |
Oregon Health & Science University |
Method for pharmacoperones correction of GnRHR mutant protein misfolding
|
|
US20060148767A1
(en)
|
2001-12-06 |
2006-07-06 |
George Cioca |
Use of acyl salicylates as heat shock inducers
|
|
US20050137223A1
(en)
|
2003-11-12 |
2005-06-23 |
Amicus Therapeutics, Inc. |
Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
|
|
EP3782655A1
(en)
|
2005-05-17 |
2021-02-24 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
|
ES2485369T3
(es)
|
2005-06-08 |
2014-08-13 |
Amicus Therapeutics, Inc. |
Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
|
|
WO2007098229A2
(en)
|
2006-02-21 |
2007-08-30 |
Michigan State University |
Geldanamycin derivatives and method of use thereof
|
|
WO2007131034A1
(en)
|
2006-05-03 |
2007-11-15 |
The Regents Of The University Of Michigan |
Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
|
|
MX351004B
(es)
|
2006-05-16 |
2017-09-26 |
Nat Institutes Of Health |
Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
|
|
WO2007140212A2
(en)
|
2006-05-24 |
2007-12-06 |
Amicus Therapeutics, Inc. |
Tartrate salt of isofagomine and methods of use
|
|
DK2040548T3
(da)
|
2006-06-23 |
2012-08-13 |
Amicus Therapeutics Inc |
Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
|
|
US8143269B2
(en)
*
|
2008-10-03 |
2012-03-27 |
Calcimedica, Inc. |
Inhibitors of store operated calcium release
|
|
KR20120117905A
(ko)
|
2010-01-28 |
2012-10-24 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
프로테아좀 활성을 향상시키는 조성물 및 방법
|
|
WO2011127333A2
(en)
*
|
2010-04-09 |
2011-10-13 |
University Of Louisville Research Foundation, Inc. |
Compounds for treating disease, for administering, and for pharmaceutical compositions
|
|
WO2012078902A2
(en)
|
2010-12-08 |
2012-06-14 |
Proteostasis Therapeutics, Inc. |
Proteostasis regulators
|
|
WO2012078909A1
(en)
|
2010-12-08 |
2012-06-14 |
Proteostasis Therapeutics, Inc. |
Thiazolpyrimidine proteostasis regulators
|
|
WO2012154880A1
(en)
|
2011-05-09 |
2012-11-15 |
Proteostasis Therapeutics, Inc. |
Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
|
|
TR201906779T4
(tr)
|
2011-05-12 |
2019-05-21 |
Proteostasis Therapeutics Inc |
Proteostaz regülatörleri.
|
|
EP2806876A4
(en)
|
2012-01-25 |
2016-03-02 |
Proteostasis Therapeutics Inc |
Proteasome activity enhancing compounds
|
|
WO2013112706A1
(en)
|
2012-01-25 |
2013-08-01 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating compounds
|
|
WO2014116228A1
(en)
*
|
2013-01-25 |
2014-07-31 |
President And Fellows Of Harvard College |
Usp14 inhibitors for treating or preventing viral infections
|
|
AU2014302458A1
(en)
|
2013-06-26 |
2015-12-24 |
Proteostasis Therapeutics, Inc. |
Methods of modulating CFTR activity
|
|
WO2015073528A1
(en)
|
2013-11-12 |
2015-05-21 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|
|
AU2015229117A1
(en)
|
2014-03-13 |
2016-09-29 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
|
CA2942386A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
EP3157917B1
(en)
|
2014-06-19 |
2020-03-18 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
|
CN104478780B
(zh)
*
|
2014-11-17 |
2017-04-19 |
华东师范大学 |
酰基吡咯类小分子有机化合物及其衍生物、用途及其制备方法
|
|
WO2016105468A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
US10738011B2
(en)
|
2014-12-23 |
2020-08-11 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
WO2016105477A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
US10548878B2
(en)
|
2015-07-24 |
2020-02-04 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods of increasing CFTR activity
|
|
US20190022071A1
(en)
|
2015-08-31 |
2019-01-24 |
Proteostasis Therapeutics, Inc. |
Methods of treating pulmonary diseases and disorders
|
|
SG11201802798WA
(en)
|
2015-10-06 |
2018-05-30 |
Proteostasis Therapeutics Inc |
Compounds, compositions, and methods for modulating cftr
|
|
MA44126A
(fr)
|
2015-12-22 |
2018-10-31 |
Proteostasis Therapeutics Inc |
Méthodes de traitement de maladies et troubles pulmonaires
|
|
WO2017177124A1
(en)
|
2016-04-07 |
2017-10-12 |
Proteostasis Therapeutics, Inc. |
Silicone atoms containing ivacaftor analogues
|
|
AU2017264612A1
(en)
|
2016-05-09 |
2018-11-22 |
Proteostasis Therapeutics, Inc. |
Methods of identifying CFTR modulators
|
|
ES2954658T3
(es)
|
2016-06-21 |
2023-11-23 |
Proteostasis Therapeutics Inc |
Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
|
|
CA3041676A1
(en)
|
2016-10-26 |
2018-05-03 |
Daniel Parks |
Pyridazine derivatives, compositions and methods for modulating cftr
|
|
US20190248779A1
(en)
|
2016-10-26 |
2019-08-15 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
EP3532461A1
(en)
|
2016-10-26 |
2019-09-04 |
Proteostasis Therapeutics, Inc. |
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
|
|
CA3061476A1
(en)
|
2017-04-28 |
2018-11-01 |
Proteostasis Therapeutics, Inc. |
4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
|
|
US20210369749A1
(en)
|
2017-10-06 |
2021-12-02 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
WO2020006269A1
(en)
*
|
2018-06-27 |
2020-01-02 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|